Brief: Ngm Amends Collaboration With Merck To Focus Primarily On Advancing Novel Medicines For Retinal And Cardiovascular And Metabolic Diseases
01/07/2021 12:06
July 1 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM AMENDS COLLABORATION WITH MERCK TO FOCUS PRIMARILY ON
ADVANCING NOVEL MEDICINES FOR RETINAL AND CARDIOVASCULAR AND
METABOLIC (CVM) DISEASES
* NGM BIOPHARMACEUTICALS INC - TO EXTEND THEIR ONGOING
COLLABORATION THROUGH MARCH 2024 BUT WITH A NARROWER SCOPE
* NGM BIOPHARMACEUTICALS - UNDER TERMS OF AMENDED
COLLABORATION,
MERCK WILL PROVIDE ABOUT $120 MILLION IN RESEARCH AND
DEVELOPMENT FUNDING TO NGM THROUGH MARCH 2024
Source text for Eikon: ID:nGNX1ghDWP
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors